In vitro and in vivo studies have found that the inhibition of the CXCL12/CXCR4 biological axis in liver fibrosis can protect against the activation and migration of HSCs, and thus attenuates liver fibrosis (Liu et al., 2016; Qin L. et al., 2018; Sung et al., 2018; Ullah et al., 2019). The gene discussed is CXCR4; the disease is Hepatic fibrosis.